Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised

MT Newswires Live

2024-10-31

Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.

Analysts' estimates were not readily available for comparison.

Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.

Analysts surveyed by Capital IQ expected 1.079 trillion yen.

The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.

Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479713907"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479713907\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479713907?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479713907","market":"fut","top_or_hot":-1,"title":"Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.</p><p>Analysts' estimates were not readily available for comparison.</p><p>Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.</p><p>Analysts surveyed by Capital IQ expected 1.079 trillion yen.</p><p>The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.</p><p>Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-10-31 16:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.</p><p>Analysts' estimates were not readily available for comparison.</p><p>Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.</p><p>Analysts surveyed by Capital IQ expected 1.079 trillion yen.</p><p>The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.</p><p>Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479713907","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479713907","pubTimestamp":1730364982,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.Analysts' estimates were not readily available for compariso","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"武田制药第二财季核心盈利、营收增长；上调财年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.Analysts' estimates were not readily available for comparison.Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.Analysts surveyed by Capital IQ expected 1.079 trillion yen.The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}